BioCentury
ARTICLE | Strategy

Seragen's just-in-time partnership

July 18, 1994 7:00 AM UTC

Seragen Inc., with less than six months of cash, has found a strategic alliance in the nick of time.

The company said Friday that it had signed a letter of intent giving Eli Lilly and Co. exclusive worldwide rights to SRGN's Interleukin-2 Fusion Toxin in cancer...